In breast cancers, the VDR promoter was significantly hypermethylated (65%) than in normal breast tissue (15%), supporting the proposed mechanism of silencing VDR expression through promoter hypermethylation, which appears linked to 1,25(OH)2D3 sensitivity [35]. Here, VDR is linked to breast carcinoma.